CVS Caremark (NYSE: CVS ) is expected to report Q4 earnings on Feb. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CVS Caremark's revenues will increase 10.0% and EPS will grow 23.6%.
The average estimate for revenue is $31.14 billion. On the bottom line, the average EPS estimate is $1.10.
Last quarter, CVS Caremark logged revenue of $30.23 billion. GAAP reported sales were 13% higher than the prior-year quarter's $26.67 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.85. GAAP EPS of $0.79 for Q3 were 22% higher than the prior-year quarter's $0.65 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 18.7%, 70 basis points worse than the prior-year quarter. Operating margin was 6.0%, 10 basis points better than the prior-year quarter. Net margin was 3.3%, about the same as the prior-year quarter.
The full year's average estimate for revenue is $122.89 billion. The average EPS estimate is $3.40.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,685 members out of 1,750 rating the stock outperform, and 65 members rating it underperform. Among 458 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 447 give CVS Caremark a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $52.36.
Is CVS Caremark the right retailer for your portfolio? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average retailing powerhouse. Click here for instant access to this free report.